The effect of growth hormone therapy on craniofacial growth and dental maturity in children with Down syndrome.
Craniofacial growth was evaluated 3 years after termination of growth hormone (GH) therapy in ten Down syndrome (DS) children. The control group consisted of 16 age-matched children with DS. The treatment started at 6-9 months of age, and the duration was 36 months. There were no statistically significant differences in craniofacial development between DS children treated with GH or DS children not treated. In conclusion, the results of this study indicate that GH therapy for 36 months in children with DS did not change the craniofacial morphology compared to a group of DS children not given GH.
Carlstedt
K
K
Department of Pediatric Dentistry, Karolinska Institutet, Huddinge, Sweden.
Annerén
G
G
Huggare
J
J
Modéer
T
T
Dahllöf
G
G
D002508:Cephalometry; D002648:Child; D002675:Child, Preschool; D004314:Down Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D019382:Human Growth Hormone / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008445:Maxillofacial Development / Q000187:drug effects*; D012886:Skull / Q000254:growth & development*; D014070:Tooth / Q000187:drug effects* / Q000254:growth & development
D019382:Human Growth Hormone